Bain Capital Life Sciences Investors, LLC - CRINETICS PHARMACEUTICALS IN ownership

CRINETICS PHARMACEUTICALS IN's ticker is CRNX and the CUSIP is 22663K107. A total of 81 filers reported holding CRINETICS PHARMACEUTICALS IN in Q1 2021. The put-call ratio across all filers is - and the average weighting 0.2%.

Quarter-by-quarter ownership
Bain Capital Life Sciences Investors, LLC ownership history of CRINETICS PHARMACEUTICALS IN
ValueSharesWeighting
Q3 2023$37,934,916
-8.7%
1,275,552
-44.7%
4.24%
-0.9%
Q2 2023$41,546,155
+112105.0%
2,305,5580.0%4.28%
-7.5%
Q1 2023$37,027
-12.2%
2,305,5580.0%4.63%
-1.8%
Q4 2022$42,192
-99.9%
2,305,5580.0%4.72%
-12.8%
Q3 2022$45,281,000
+5.3%
2,305,5580.0%5.40%
+7.2%
Q2 2022$42,999,000
-3.5%
2,305,558
+13.6%
5.04%
+16.5%
Q1 2022$44,552,000
-22.7%
2,029,7010.0%4.33%
-5.4%
Q4 2021$57,664,000
+63.1%
2,029,701
+20.8%
4.57%
+108.5%
Q3 2021$35,358,000
+11.7%
1,679,7010.0%2.19%
+5.7%
Q2 2021$31,662,000
+93.4%
1,679,701
+56.8%
2.08%
+123.8%
Q1 2021$16,371,000
+8.3%
1,071,4280.0%0.93%
-2.3%
Q4 2020$15,118,000
-10.0%
1,071,4280.0%0.95%
-39.4%
Q3 2020$16,789,000
-10.6%
1,071,4280.0%1.56%
-20.4%
Q2 2020$18,771,0001,071,4281.97%
Other shareholders
CRINETICS PHARMACEUTICALS IN shareholders Q1 2021
NameSharesValueWeighting ↓
Saturn V Capital Management LP 1,126,579$33,504,45914.02%
New Leaf Venture Partners, L.L.C. 141,000$4,193,3405.38%
First Light Asset Management, LLC 1,583,329$47,088,2044.47%
Paradigm Biocapital Advisors LP 2,178,737$64,795,6384.40%
Bain Capital Life Sciences Investors, LLC 1,275,552$37,934,9164.24%
Altium Capital Management LP 262,000$7,791,8804.06%
5AM Venture Management, LLC 462,286$13,748,3863.96%
MPM BioImpact LLC 479,053$14,247,0363.80%
Affinity Asset Advisors, LLC 450,000$13,383,0003.76%
Opaleye Management Inc. 370,000$11,003,8003.58%
View complete list of CRINETICS PHARMACEUTICALS IN shareholders